ES2181849T3 - Procedimiento para minimizar la perdida osea. - Google Patents

Procedimiento para minimizar la perdida osea.

Info

Publication number
ES2181849T3
ES2181849T3 ES96304180T ES96304180T ES2181849T3 ES 2181849 T3 ES2181849 T3 ES 2181849T3 ES 96304180 T ES96304180 T ES 96304180T ES 96304180 T ES96304180 T ES 96304180T ES 2181849 T3 ES2181849 T3 ES 2181849T3
Authority
ES
Spain
Prior art keywords
sub
formula
loss
rent
minimize
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96304180T
Other languages
English (en)
Inventor
George Joseph Cullinan
Steven Anthony Fontana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2181849T3 publication Critical patent/ES2181849T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Glass Compositions (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UN METODO PARA MINIMIZAR LA PERDIDA DE HUESO MEDIANTE UN COMPUESTO DE FORMULA II O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ESTE COMPUESTO. ESTA FORMULA II SE ADMINISTRA A UN MAMIFERO QUE NECESITE TRATAMIENTO, CONJUNTA O SECUENCIALMENTE CON UNA CANTIDAD EFICAZ DE UN COMPUESTO DE FORMULA I DONDE R{SUP,1} ES, INDEPENDIENTEMENTE, -H, -OH, -O(C{SUB,1}C{SUB,4} ALQUIL), -OCOC{SUB,6}H{SUB,5}, -OCO(C{SUB,1}-C{SUB,6} ALQUIL) O -OSO{SUB,2}(C{SUB,4}-C{SUB,6} ALQUIL) Y R{SUP,2} ES 1PIPERIDINIL, 1-PIRROLIDINIL, METIL-1-PIRROLIDINIL, DIMETIL-1PIRROLIDINIL, 4-MORFOLINO, DIMETILAMINO, DIETILAMINO P 1HEXAMETILENIMINO O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLE. TAMBIEN SE PROPORCIONA UN METODO PARA MINIMIZAR LA PERDIDA DE HUESO MEDIANTE LA ADMINISTRACION DE UN COMPUESTO DE LA FORMULA II Y, DE FORMA CONJUNTA O SECUENCIAL, UN AGENTE ANABOLICO OSEO. TAMBIEN SE INCLUYEN LAS COMPOSICIONES FARMACEUTICAS.
ES96304180T 1995-06-06 1996-06-06 Procedimiento para minimizar la perdida osea. Expired - Lifetime ES2181849T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/467,475 US5599822A (en) 1995-06-06 1995-06-06 Methods for minimizing bone loss

Publications (1)

Publication Number Publication Date
ES2181849T3 true ES2181849T3 (es) 2003-03-01

Family

ID=23855853

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96304180T Expired - Lifetime ES2181849T3 (es) 1995-06-06 1996-06-06 Procedimiento para minimizar la perdida osea.

Country Status (22)

Country Link
US (1) US5599822A (es)
EP (1) EP0747054B1 (es)
JP (1) JPH11507051A (es)
KR (1) KR19990022498A (es)
CN (1) CN1192145A (es)
AU (1) AU696209B2 (es)
BR (1) BR9608389A (es)
CA (1) CA2223055A1 (es)
CO (1) CO4700446A1 (es)
CZ (1) CZ382997A3 (es)
DE (1) DE69623074T2 (es)
EA (1) EA000763B1 (es)
ES (1) ES2181849T3 (es)
HU (1) HUP9900849A3 (es)
IL (1) IL118590A (es)
NO (1) NO975581L (es)
PL (1) PL323935A1 (es)
TR (1) TR199701507T1 (es)
TW (1) TW372969B (es)
WO (1) WO1996039138A1 (es)
YU (1) YU34396A (es)
ZA (1) ZA964778B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
AU7993500A (en) * 1999-11-15 2001-05-30 New Millennium Pharmaceutical Research, Inc. Intranasal administration of raloxifene and tamoxifen
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1180364A1 (en) * 2000-08-15 2002-02-20 Octagene GmbH Steroid hormones as transfer agents
DE60327931D1 (de) 2002-07-22 2009-07-23 Lilly Co Eli Selektive östrogenrezeptor modulatoren, die eine phenylsulfonyl-gruppe enthalten
CN101151048A (zh) 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
JP5007427B2 (ja) * 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
AU2006299887A1 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. PTH formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US11253498B2 (en) * 2017-06-01 2022-02-22 Nexyon Biotech Co., Ltd. Pharmaceutical composition for treatment of bone-related disease
CN108785264A (zh) * 2018-07-03 2018-11-13 威海贯标信息科技有限公司 一种达那唑片剂组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) * 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
DE69623074D1 (de) 2002-09-26
YU34396A (sh) 1999-07-28
ZA964778B (en) 1997-12-08
BR9608389A (pt) 1999-05-04
HUP9900849A3 (en) 1999-11-29
WO1996039138A1 (en) 1996-12-12
EA199800013A1 (ru) 1998-06-25
CA2223055A1 (en) 1996-12-12
HUP9900849A2 (hu) 1999-09-28
US5599822A (en) 1997-02-04
TR199701507T1 (xx) 1998-02-21
EP0747054A3 (en) 1997-03-05
NO975581D0 (no) 1997-12-03
IL118590A0 (en) 1996-10-16
CO4700446A1 (es) 1998-12-29
IL118590A (en) 1999-10-28
NO975581L (no) 1997-12-03
AU696209B2 (en) 1998-09-03
EA000763B1 (ru) 2000-04-24
AU6043096A (en) 1996-12-24
EP0747054A2 (en) 1996-12-11
PL323935A1 (en) 1998-04-27
EP0747054B1 (en) 2002-08-21
KR19990022498A (ko) 1999-03-25
CN1192145A (zh) 1998-09-02
DE69623074T2 (de) 2003-05-08
CZ382997A3 (cs) 1998-09-16
JPH11507051A (ja) 1999-06-22
TW372969B (en) 1999-11-01

Similar Documents

Publication Publication Date Title
ES2165969T3 (es) Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios.
ES2143539T3 (es) Uso de un agente fotosensibilizador.
ES2099428T3 (es) Composiciones farmaceuticas para inhalacion.
ATE189218T1 (de) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
ES2167720T3 (es) Compuestos de 1-fenilpirazol y aplicaciones medicinales de los mismos.
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
PA8467401A1 (es) Procedimiento para tratar la insuficiencia cardiaca
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
GT199700037A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
MX9206309A (es) Metodo y composicion para tratar tumores que tienen alta actividad de tirosinasa.
NO20003313L (no) Terapeutiske midler
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
EA199800013A1 (ru) Способы минимизации остеопороза
DE3888778D1 (de) Polyamin-Derivate als antineoplastische Wirkstoffe.
ES2093246T3 (es) Compuestos de benzazepina terapeuticos.
KR970703152A (ko) 치료제 용도의 피리딜비스인산염(pyridylbisphosphonates for use as a therapeutical agent)
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
ES2142545T3 (es) Minimizacion de la perdida osea por combinaciones de antiestrogenos.
ATE244011T1 (de) Unterdrückung der thromboxanspiegel durch perkutane verabreichung von aspirin
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.